Best Practices of Indexes Used for Value Evaluation of Drug Molecules in In-Licensing for Pre-Clinical Discovery
The client wanted to improve the quality and quantity of preclinical/discovery project pipeline by in-licensing procedure, and in this regard wanted to understand the best practices of key indexes (qualitative and /or quantitative) used for value evaluation of the drug candidates during discovery phase for both in-licensing and internal research. The client had the following objectives: To determine the factors considered to arrive at the value for products that the client intends to in-license Key parameters or weighing methodology adopted for developing an index that helps them arrive at a value of drug molecule in different stages of discovery To find how these indexes aid internal decision-making process in the drug pipeline
Research findings were delivered to the client as a custom report that included: Data on products in-licensed by the target companies in the last five years Key factors used by companies for weighing multiple indexes Best practices of key indexes (qualitative and /or quantitative) used for value evaluation of the drug candidates Utilization of indexes in decision making for pipeline drugs Analysis for each stage of drug discovery and comparative analysis for in-licensing and in-house research Conclusions and recommendations
We conducted research through: Primary research: 10+ interviews with key executives involved in the decision-making process of in-licensing and drug value evaluations in the target companies Secondary research: We referred to various resources such as news sources and blogs, company filings, annual reports, and other publicly available information
The client was very satisfied with the findings of our study. The research findings helped the client in enhancing the decision-making process in the drug pipeline.